A 56-year-old male was admitted to our hospital with lymphocytosis (16.4 X 109/l; 79% lymphocytes including 50% small lymphocytes), generalized lymphadenopathy, massive spleno megaly, and heavily infiltrated bone marrow. Immunophenotype analysis of the neoplastic cells in the bone marrow revealed that they were B cells (CD20+CD19+Ial+sIgM+) positive for CD10. By contrast, the cells in the lymph node were CD20+CD19+Ial+sIgM+ but negative for CD10. The patient was tentatively diagnosed as having lymphosarcoma cell lymphoma, however, the final diagnosis was leukemic phase of intermediate lymphocytic lymphoma. We concluded that CD10+ neoplastic cells in the bone marrow and peripheral blood had dif ferentiated to CD10-cells. (Internal Medicine 31: 553-556, 1992) 
The disease entity of lymphoproliferative disorders includes chronic lymphocytic leukemia (CLL) and nonHodgkin's lymphoma (NHL) (1-4). The utilization of cell surface marker analysis has made it possible to identify not only cellular ontogeny but also the maturation stage of normal counterparts of lymphocytes (5, 6) . In some patients with B cell type lymphoproliferative disorder, the differential diagnosis between CLL and NHL in the leukemic phase is difficult, even when the surface markers of neoplastic cells are analyzed. We report a case with clinical findings involving central nervous system and cytological features of the circulating cells compatible with so-called lymphosarcoma cell leukemia (LSCL) . The maturation level of neoplastic cells in the bone marrow (BM) and peripheral blood (PB) was different from that in the lymph node and cerebrospinal fluid (SCF), indicating that the unusual clinical manifestation was due to the unique characteristics of the neoplastic cells with CD10 antigen.
A 56-year-old male complained of lumbago in October 1986 and was admitted to our hospital in December 1986. Physical examination on admission revealed a massive splenomegaly and mild hepatomegaly (20cm and 2 cm below costal margin). Generalized lymphade nopathy was also noted in the cervical, axillary, and inguinal regions. The leukocyte count was 16.4 X 109/l, including 79% lymphocytes (Table 1) ; about 50% of which resembled mature small lymphocytes, but their chromatin patterns were somewhat fine compared to those of normal mature lymphocytes. The remaining 50% had relatively large nuclei with a fine chromatin pattern, and prominent nucleoli (Fig. 1A) . The nuclear contour of the later cells was occasionally clefted and folded, and they had irregular cytoplasmic projections.
Bone marrow examination revealed a nucleated cell count of 284 x 109/l, including 78.8% lymphocytes with out prominent nucleoli, but some of them had indented nuclei (Fig. IB) . The neoplastic cells in the BM were CD20+CD19+Ial+sIgM+CD10+ by flowcytometric analysis ( Table 2) . Biopsy of the inguinal lymph node (Fig. 2) . The pathological diagnosis was diffuse and small cleaved NHL, according to the working formulation of the Non-Hodgkin's Lymphoma Pathologic Classification. The neoplastic cells in the excised lymph node had CD20+CD19+Ial+sIgM+ (lambda chain) but were negative for CD10 (Table 2) . Monoclonal gammopathy was not detected. The patient was given four courses of CHOP therapy (cyclophosphamide, doxorubicin, vincristine, and pred nisolone). In May 1987, splenomegaly and lymphadeno pathy had disappeared, however, the BM was still heavily infiltrated with small lymphocytes (75.6%) and the cir culating lymphocytes count remained high. Because the patient's status was generally improved and the hemato logic conditions were not progressive, he was followed up as an out-patient and treated with intermittent oral cyclophosphamide (lOO mg/day). In May 1988, the patient again manifested spleno megaly (10 cm below the costal margin) with generalized lymphadenopathy and was readmitted. Bone marrow aspiration revealed lymphocytic infiltration and an ultra sonogram demonstrated intra-abdominal lymphadeno pathy. Thus, the patient was again treated with CHOP therapy and this regimen was effective. However, the patient complained of neurologic symptoms, including a tingling sensation in both lower extremities, headache, and nausea. A spinal tap revealed lymphocytic infiltration of more than 1 X 109/l: the neoplastic cells were CD20+ CD19+Ial+sIgM+CD10- (Table 2 ). Although the patient was treated with intrathecal methotrexate in jection (15mg, 8 times), cytosine arabinoside (20mg, 6 times), and skull irradiation with generalized chemo therapy, optic and facial nerve palsy appeared. These treatments were partially effective in cytoreduction, however, the patient died of sepsis on February 6, 1989.
Discussion
Chronic lymphocytic leukemia and NHL in the leukemic phase are included in lymphoproliferative disorders, and patients with these two neoplastic forms sometimes exhibit similar clinical features (1-4). There fore, the differential diagnosis of these two neoplasias remains controversial. On the other hand, LSCL has been frequently used and encompasses a variant form of CLL in European and American reports (7-9), present ing clinically without lymphoma with a poorer prognosis than those with typical CLL (8). Recently, however, the trend has been to abolish this diagnosis in the classifi cation of lymphoma to avoid confusion, and the entity of leukemic manifestation of NHL currently includes LSCL (10). We first thought that the patient suffered from CLL or NHL in the leukemic phase. However, the morphology of the neoplastic cells led us to consider the diagnosis of LSCL. First, the count of circulating lymphocytes on admission was very high (13 xlO9/l), but they had CD10 antigen with heterogenous morphologies. Second, the course of disease was relatively progressive with invasive nature. His general condition, including lymphadeno pathy and splenomegaly, improved after chemotherapy, although the neoplastic cells remained in the BM and PB with high occurence rates. Finally, the morphology of neoplastic cells in the PB was different from those of typical CLL and those of leukemic manifestation of follicular lymphoma (10, ll): some of the neoplastic cells in this case had nucleoli and clefted nuclei, but the clefts were not very narrow as those seen in the leukemic phase of follicular lymphoma. These clinical and cytologic features suggest the presence of the spectrum of chronic lymphoid leukemia consisting of CLL and leukemic NHL. Currently, the diagnosis of LSCL is considered to be included as the leukemic phase of intermediate or mantle zone (centrocytic) NHL (12, 13). The reason, however, that we hesitated to diagnose it as the leukemic phase of intermediate lymphocytic lymphoma is that the main lesion in this patient seemed to be BM and/or PB, since after the first chemotherapy lymphadenopathy and splenomegaly disappered, whereas the BM infiltration abnormal cells in the PB remained. 12, 14) or it represents the nature of the disease (14), since the current case also showed the dissociation of CD10 expression between BM and LN. Therefore, detailed investigations of patients with B-cell lympho proliferative disease are needed to clarify their biological and hematological significance in the spectrum of B-cell type neoplasias.
